We Bioperfectus today solemnly and sincerely declare that our products:COVID-19 Coronavirus Real Time PCR Kit &COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit STAY NO DROP IN SENSITIVITY & SPECIFICITY IN FACE OF 9 MAJOR VARIANTS OF SARS-COV-2.
Information about 9 Major SARS-CoV-2 Variants
|
Lineage
|
First Detected
|
Earliest Day
|
Spike Protein Substitutions
|
Attributes
|
|
B.1.1.7
|
United Kingdom
|
February 7, 2020
|
Δ69/70, Δ144, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)
|
~50% increased transmission
Likely increased severity based on hospitalizations and case fatality rates
Minimal impact on neutralization by EUA monoclonal antibody treatments
Minimal impact on neutralization by convalescent and post-vaccination sera
|
|
B.1.351
|
South Africa
|
May 11, 2020
|
D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V
|
~50% increased transmission
Reduction in neutralization by some, but not all EUA monoclonal antibody treatments
Moderate reduction in neutralization by convalescent and post-vaccination sera
|
|
P.1
|
Japan/
Brazil
|
November 30, 2020
|
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I
|
Reduction in neutralization by some, but not all EUA monoclonal antibody treatments Reduced neutralization by convalescent and post-vaccination sera
|
|
P.2
|
Brazil
|
April 15, 2020
|
E484K, (F565L*), D614G, V1176F
|
Potential reduction in neutralization by monoclonal antibody treatments
Reduced neutralization by post-vaccination sera
|
|
B.1.525
|
United Kingdom, Nigeria
|
December 11, 2020
|
A67V, Δ69/70, Δ144, E484K, D614G, Q677H, F888L
|
Potential reduction in neutralization by monoclonal antibody treatments
Potential reduction in neutralization by convalescent and post-vaccination sera
|
|
B.1.526
|
United States-(New York)
|
November 23, 2020
|
(L5F*), T95I, D253G, (S477N*), (E484K*), D614G, (A701V*)
|
Reduced neutralization by some, but not all EUA monoclonal antibody treatments
Reduced neutralization by convalescent and post-vaccination sera
|
|
B.1.427
|
United States-(California)
|
March 15, 2020
|
L452R, D614G
|
~20% increased transmissibility
Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments
Moderate reduction in neutralization using convalescent and post-vaccination sera
|
|
B.1.429
|
United States-(California)
|
April 15, 2020
|
S13I, W152C,L452R, D614G
|
~20% increased transmissibility
Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments
Moderate reduction in neutralization using convalescent and post-vaccination sera
|
|
B.1.617
|
India
|
February 25, 2021
|
Under research
|
Under research
|
|
References:
https://cov-lineages.org/lineages.html
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
|
